Browse > Article
http://dx.doi.org/10.5483/BMBRep.2016.49.5.231

Neuropeptide Y protects kidney against cisplatin-induced nephrotoxicity by regulating p53-dependent apoptosis pathway  

Kim, Namoh (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Min, Woo-Kie (Department of Orthopaedic Surgery, Kyungpook National University Hospital)
Park, Min Hee (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Lee, Jong Kil (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Jin, Hee Kyung (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Bae, Jae-sung (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
Publication Information
BMB Reports / v.49, no.5, 2016 , pp. 288-292 More about this Journal
Abstract
Cisplatin is a platinum-based chemotherapeutic drug for treating various types of cancers. However, the use of cisplatin is limited by its negative effect on normal tissues, particularly nephrotoxicity. Various mechanisms such as DNA adduct formation, mitochondrial dysfunction, oxidative stress, and apoptosis are involved in the adverse effect induced by cisplatin treatment. Several studies have suggested that neuropeptide Y (NPY) is involved in neuroprotection as well as restoration of bone marrow dysfunction from chemotherapy induced nerve injury. However, the role of NPY in chemotherapy-induced nephrotoxicity has not been studied. Here, we show that NPY rescues renal dysfunction by reducing the expression of pro-apoptotic proteins in cisplatin induced nephrotoxicity through Y1 receptor, suggesting that NPY can protect kidney against cisplatin nephrotoxicity as a possible useful agent to prevent and treat cisplatin-induced nephrotoxicity.
Keywords
Apoptosis; Chemotherapy-induced side effect; Cisplatin; Nephrotoxicity; Neuropeptide Y;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Pabla N and Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994-1007   DOI
2 Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279   DOI
3 Pabla N, Dong G, Jiang M et al (2011) Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121, 2709-2722   DOI
4 Jia Z, Wang N, Aoyagi T, Wang H, Liu H and Yang T (2011) Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int 79, 77-88   DOI
5 Oh GS, Kim HJ, Choi JH et al (2014) Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney Int 85, 547-560   DOI
6 Sah R and Geracioti TD (2013) Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatry 18, 646-655   DOI
7 Santos-Carvalho A, Elvas F, Alvaro AR, Ambrósio AF and Cavadas C (2013) Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis 4, e636   DOI
8 Körner M, Waser B and Reubi JC (2004) Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 84, 71-80   DOI
9 Gonçalves J, Ribeiro CF, Malva JO and Silva AP (2012) Protective role of neuropeptide Y Y2 receptors in cell death and microglial response following methamphetamine injury. Eur J Neurosci 36, 3173-3183   DOI
10 Park MH, Jin HK, Min WK et al (2015) Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow. EMBO J 34, 1648-1660   DOI
11 Humanes B, Lazaro A, Camano S et al (2012) Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82, 652-663   DOI
12 Panesso MC, Shi M, Cho HJ et al (2014) Klotho has dual protective effects on cisplatin-induced acute kidney injury. Kidney Int 85, 855-870   DOI
13 Linkermann A, Himmerkus N, Rölver L et al (2011) Renal tubular Fas ligand mediates fratricide in cisplatin-induced acute kidney failure. Kidney Int 79, 169-178   DOI
14 Jiang M, Yi X, Hsu S, Wang CY and Dong Z (2004) Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287, F1140-1147   DOI
15 Xu Y, Ma H, Shao J et al (2015) A Role for Tubular Necroptosis in Cisplatin-Induced AKI. J Am Soc Nephrol 26, 2647-2658   DOI
16 Lim SW, Jin L, Piao SG, Chung BH et al (2015) Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Lab Invest 95, 1174-1185   DOI
17 Katagiri D, Hamasaki Y, Doi K et al (2013) Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24, 2034-2043   DOI
18 Hwang HS, Park IY, Kim DW et al (2015) PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model. BMB Rep 48, 407-412   DOI
19 Smiałowska M, Domin H, Zieba B et al (2009) Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides 43, 235-249   DOI
20 Wei Q, Dong G, Franklin J and Dong Z (2007) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72, 53-62   DOI
21 Hu L, Su P, Li R et al (2015) Knockdown of microtubule actin crosslinking factor 1 inhibits cell proliferation in MC3T3-E1 osteoblastic cells. BMB Rep 48, 583-588   DOI